RWE of the comparative effectiveness and safety of direct oral anticoagulants used to treat patients with atrial fibrillation

A large-scale, multinational RWD study conducted by UCL has shown that the direct oral anticoagulant apixaban gives the lowest risk of GI bleeding, with similar performance on stroke prevention and other side effects, when used to treat patients with irregular heartbeats. In Annals of Internal Medicine on 1 November 2022, University College London (UCL) researchers published the results of their 10-year, multinational RWD study comparing the efficacy and risk of side-effects of four of the most common direct oral anticoagulants (DOACs) used to treat patients with atrial fibrillation. The study generated RWE that apixaban gives the lowest risk of gastrointestinal...